{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-24-000011","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.981820+00:00","generated_at":"2026-06-05T15:18:18.430184+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BeiGene Q4 revenue $634M (+67% YoY); BRUKINSA sales $413M (+135%); operating loss narrows","bullets":["Record total revenue $634M in Q4 (+67% YoY) and $2.5B full year (+74%); product revenue $630.5M (+86%).","BRUKINSA global sales $413M in Q4 (+135% YoY) and $1.3B full year (+129%); U.S. revenue $313M in Q4.","GAAP operating loss $383.8M in Q4, down 18% YoY; adjusted operating loss $267.2M, down 28%.","FDA approved BRUKINSA label update for PFS superiority in CLL; EU approved for R/R follicular lymphoma.","Advanced pipeline: sonrotoclax Phase 3 in CLL started; BTK CDAC BGB-16673 early data; TEVIMBRA CHMP positive opinion for NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-24-000011","json":"https://secwatch.observer/filing/0001651308-24-000011.json","markdown":"https://secwatch.observer/filing/0001651308-24-000011.md","text":"https://secwatch.observer/filing/0001651308-24-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000011/0001651308-24-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000011/bgne-20240226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T15:18:18.430184+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d51b76b5b1106b03e89d3df1f49976867592849","claim":"BeOne Medicines Ltd. reported three months and year ended December 31, 2023 results: revenue $634.4 million and $2.5 billion.","evidence_excerpt":"EX-99.1 (EX-99.1) --- BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates • Continued rapid global growth with record total revenues of $634 million in fourth quarter and $2.5 billion in full-year 2023, increases of 67% and 74% from the prior-year periods • Strengthened leadership in hematology with global BRUKINSA®","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000011/0001651308-24-000011-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months and year ended December 31, 2023"},{"label":"Revenue","value":"$634.4 million and $2.5 billion"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}